|
HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.
As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence in Hong Kong's long-term potential as a center for medical innovation.
Hong Kong has a supportive government ecosystem for healthcare innovation — its strategic initiatives to advance primary care and collaborative regional frameworks provide an ideal environment for Roche to deliver tailored solutions. Whether it is AI‑enabled diagnostics or advanced therapies, Roche is committed and eager to work alongside local partners to improve patient outcomes.
Looking ahead, Roche will continue strengthening its commitment to Hong Kong's scientific landscape and supporting the Primary Healthcare Blueprint through the following initiatives:
- Strengthening Diabetes and Chronic Disease Management – Advancing Point-of-Care Testing (POCT) to promote early intervention and better management of chronic diseases and introducing the first Continuous Glucose Monitoring (CGM) technology enhanced with AI algorithms for improved diabetes management.
- Driving Innovation in Ophthalmology – Developing innovative treatments that reduce the frequency of injections for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and broadening AI Optical Coherence Tomography (AI-OCT) screenings for the public.
- Pandemic Influenza Preparedness – Working with the government to enhance preparedness and strengthen economic resilience.
- Cancer and Precision Diagnostics – Expanding localized Comprehensive Genomic Profiling (CGP) to accelerate cancer diagnosis and treatment and AI-enabled digital pathology technology to enhance smart hospital facilities.
- Pioneering First-in-Human Clinical Research and Global Antiviral Drug Trials – Collaborating with multiple stakeholders, including academia, Roche initiated its First-in-Human (FIH) clinical trials in 2025, enrolling the world's first two Chinese patients. With groundbreaking global antiviral drug trials published in leading medical journals, Roche reaffirms its commitment to strengthening Hong Kong's position as a global hub for clinical research and innovation.
Ms. Amy Ho, General Manager of Roche Hong Kong Limited, said, "Hong Kong's vibrant healthcare ecosystem and strong policy support make it an ideal hub for innovation. At Roche, we are guided by our purpose statement, 'Doing now what patients need next'—through our collaboration with OASES, we are deepening our commitment to bring breakthrough therapies and diagnostics to patients faster, while nurturing local talent and research capabilities. This collaboration is not just about investment, it's about creating long-term value for patients, healthcare professionals, and society."
Mr. Ronald Lo, General Manager, Roche Diagnostics (Hong Kong) Limited, added: "According to the World Health Organisation, 75% of deaths are caused by chronic diseases[1], prompting a global shift from treatment to prevention as a long-term investment. Roche supports the Hong Kong Government's Primary Healthcare policy by advancing cutting‑edge diagnostics in chronic disease management. Through OASES, we aim to bring advanced diagnostic solutions to more patients, foster meaningful collaborations to build a sustainable healthcare system that improves lives."
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
For more information, please contact:
Butterfly Cheung
butterfly.cheung@roche.com
Iris Lam
iris.lam.il1@roche.com
Sincere Kwan
sincere.kwan@roche.com
References
1. World Health Organisation. Noncommunicable diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (Accessed Oct 10 2025)
HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.
As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence in Hong Kong's long-term potential as a center for medical innovation.
Hong Kong has a supportive government ecosystem for healthcare innovation — its strategic initiatives to advance primary care and collaborative regional frameworks provide an ideal environment for Roche to deliver tailored solutions. Whether it is AI‑enabled diagnostics or advanced therapies, Roche is committed and eager to work alongside local partners to improve patient outcomes.
Looking ahead, Roche will continue strengthening its commitment to Hong Kong's scientific landscape and supporting the Primary Healthcare Blueprint through the following initiatives:
- Strengthening Diabetes and Chronic Disease Management – Advancing Point-of-Care Testing (POCT) to promote early intervention and better management of chronic diseases and introducing the first Continuous Glucose Monitoring (CGM) technology enhanced with AI algorithms for improved diabetes management.
- Driving Innovation in Ophthalmology – Developing innovative treatments that reduce the frequency of injections for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and broadening AI Optical Coherence Tomography (AI-OCT) screenings for the public.
- Pandemic Influenza Preparedness – Working with the government to enhance preparedness and strengthen economic resilience.
- Cancer and Precision Diagnostics – Expanding localized Comprehensive Genomic Profiling (CGP) to accelerate cancer diagnosis and treatment and AI-enabled digital pathology technology to enhance smart hospital facilities.
- Pioneering First-in-Human Clinical Research and Global Antiviral Drug Trials – Collaborating with multiple stakeholders, including academia, Roche initiated its First-in-Human (FIH) clinical trials in 2025, enrolling the world's first two Chinese patients. With groundbreaking global antiviral drug trials published in leading medical journals, Roche reaffirms its commitment to strengthening Hong Kong's position as a global hub for clinical research and innovation.
Ms. Amy Ho, General Manager of Roche Hong Kong Limited, said, "Hong Kong's vibrant healthcare ecosystem and strong policy support make it an ideal hub for innovation. At Roche, we are guided by our purpose statement, 'Doing now what patients need next'—through our collaboration with OASES, we are deepening our commitment to bring breakthrough therapies and diagnostics to patients faster, while nurturing local talent and research capabilities. This collaboration is not just about investment, it's about creating long-term value for patients, healthcare professionals, and society."
Mr. Ronald Lo, General Manager, Roche Diagnostics (Hong Kong) Limited, added: "According to the World Health Organisation, 75% of deaths are caused by chronic diseases[1], prompting a global shift from treatment to prevention as a long-term investment. Roche supports the Hong Kong Government's Primary Healthcare policy by advancing cutting‑edge diagnostics in chronic disease management. Through OASES, we aim to bring advanced diagnostic solutions to more patients, foster meaningful collaborations to build a sustainable healthcare system that improves lives."
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
For more information, please contact:
Butterfly Cheung
butterfly.cheung@roche.com
Iris Lam
iris.lam.il1@roche.com
Sincere Kwan
sincere.kwan@roche.com
References
1. World Health Organisation. Noncommunicable diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (Accessed Oct 10 2025)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub
Bringing exclusive sports and lifestyle travel to a new level of convenience and exclusivity
HONG KONG, April 1, 2026 /PRNewswire/ -- CSTS Enterprises, together with its subsidiary Connexus Travel, announced a strategic partnership with JETBAY, Asia's largest private jet charter platform, to deliver premium, bespoke travel and hospitality experiences to clients across Asia.
The collaboration brings together CSTS' worldclass sports and leisure hospitality expertise, Connexus Travel's 78 years of trusted corporate travel management, and JETBAY's award- winning door-to-door private aviation experience. Together, the companies will design seamless, high-end itineraries that connect sports fans, corporate clients, and luxury travellers to major global events — including the World Cup 2026, international sporting tournaments, and premium lifestyle destinations.
Under the partnership, CSTS will leverage JETBAY's extensive global aircraft network and on-demand charter services to enhance its end-to-end solutions for global clients.
From tailored matchday journeys and corporate travel programmes to bespoke leisure itineraries, our clients will enjoy fully integrated experiences combining stadium hospitality, premium ground services, and curated cultural activities — all backed by real-time support and dedicated relationship management.
"Travel is no longer about simply getting from A to B — it's about creating meaningful, shareable moments before, during, and after the event," said Abel Zhao, Chief Executive Officer and Executive Director of CSTS. "By partnering with JETBAY, we aim to elevate our clients' journeys beyond the ticket, delivering a truly integrated 'experience economy' where convenience, comfort, and exclusivity come together."
"Our goal is to make worldclass events more accessible to time sensitive business and leisure travellers, and this collaboration is a big step forward," said Vivian Zhang, Co- founder of JETBAY. "By partnering with CSTS, JETBAY can bring a new level of comfort and convenience to fans travelling for major global events."
The partnership reflects growing demand in the Asia market for premium, experience- driven travel products. As global sports and entertainment continue to drive audience engagement and travel demand, CSTS and JETBAY aim to become the go-to providers for clients seeking sophisticated, end-to-end solutions that marry worldclass travel technology with hands-on human service.
About CSTS Enterprises Inc.
Headquartered in Hong Kong, CSTS Enterprises is an innovative media, entertainment, sports, and travel-technology group. CSTS is dedicated to becoming a global expert in developing and managing innovative, end-to-end integrated marketing solutions and services that connect international intellectual properties – such as major sports and entertainment events – with regional and local brands.
At its core, CSTS is a provider of innovative solutions across corporate travel, integrated marketing, and advanced technology services. Through deep knowledge of the industry and advanced technologies, CSTS delivers tech-enabled efficiency and cost-effective travel programs, transforming corporate travel into a seamless, value-driven experience.
For more information, please visit https://csts-enterprises.com/ or follow our Linkedin for latest updates.
About Connexus Travel Limited
Connexus Travel (formerly known as Swire Travel) 全旅達國際旅遊有限公司, License No: (350001), one of the earliest Hong Kong-registered and award-winning travel agencies, has been a trusted household name for over 78 years. As an innovative travel management company in the region, it delivers seamless, tech-enabled experiences, combining personalized 24/7 support with innovative digital platforms. Connexus Travel offers a full spectrum of travel services—including corporate, leisure, MICE, and sports/lifestyle travel—and plays a key role in promoting global events like the FIFA World Cup and Formula 1.
Connexus Travel is a subsidiary of CSTS Enterprises.
About JETBAY
JETBAY is Asia's largest private jet charter platform, leveraging proprietary AI technology to provide clients with the most efficient and cost-effective private aviation solutions globally. Headquartered in Singapore and backed by over 20 years of industry expertise, JETBAY offers a seamless booking experience and unparalleled service through its international offices in New York, London, Dubai, Hong Kong, Jakarta, and Shanghai. The company is dedicated to upholding the highest standards of safety, privacy, and luxury for its discerning clientele.
Forward-Looking Statements
This press release contains statements that are forward-looking statements. These forward-looking statements can be identified by terminology such as "anticipate," "estimate," "forecast," "plan," "project," "potential," "continue," "ongoing," "expect," "aim," "believe," "intend," "may," "should," "will," "is/are likely to," "could" and similar statements. Statements that are not historical facts, including statements about CSTS's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. All information provided in this press release is as of the date of this press release, and CSTS does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Media Contacts
Wicky Yu
Corporate Communications, CSTS Enterprises Inc.
Phone: +852 2122 8545
Email: communications@csts-enterprises.com
Website: https://csts-enterprises.com/
Cody Lee Kar Hao
Branding and Marketing Manager, JETBAY
Phone: +65 6562 2988
Email: karhaolee@jet-bay.com
Website: https://www.jet-bay.com/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CSTS Enterprises and JETBAY Announce Strategic Partnership to Elevate Sports and Leisure Travel Experiences
